BC
Broadwood Capital Portfolio holdings
AUM
$1.53B
This Quarter Return
+14.04%
1 Year Return
+36.91%
3 Year Return
+67.63%
5 Year Return
+132.65%
10 Year Return
+697.91%
AUM
$1.33B
AUM Growth
+$1.33B
(+13%)
Cap. Flow
-$31.8M
Cap. Flow
% of AUM
-2.39%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
2
Reduced
2
Closed
–
Top Buys
| 1 |
Lineage Cell Therapeutics
LCTX
|
$9.96M |
| 2 |
STAAR Surgical
STAA
|
$8.83M |
Top Sells
| 1 |
Serina Therapeutics
SER
|
$39.2M |
| 2 |
Monster Beverage
MNST
|
$11.4M |
Sector Composition
| 1 | Consumer Staples | 36.95% |
| 2 | Healthcare | 36.24% |
| 3 | Industrials | 17.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Monster Beverage
MNST
$60.9B
| $492M | 36.95% | 8,295,690 -192,327 | -2% | -$11.4M |
|
|
2
STAAR Surgical
STAA
$1.36B
| $412M | 30.97% | 10,768,430 +230,595 | +2% | +$8.83M |
|
3
Axon Enterprise
AXON
$58.7B
| $238M | 17.87% | 760,062 | – | – |
|
4
iShares Russell 2000 ETF
IWM
$67B
| $119M | 8.94% | 566,000 | – | – |
|
|
5
Lineage Cell Therapeutics
LCTX
$267M
| $61.7M | 4.63% | 41,666,255 +6,730,770 | +19% | +$9.96M |
|
|
IMDX
6
Insight Molecular Diagnostics Inc. Common Stock
IMDX
$72.4M
| $7.35M | 0.55% | 2,509,066 | – | – |
|
|
7
Serina Therapeutics
SER
$54.5M
| $1.15M | 0.09% | 85,219 -2,911,937 | -97% | -$39.2M |
|